Lumida
/AFYA
⌘K
Afya Ltd

Afya Ltd

AFYA
$13.90USD-1.84%-0.26 today

MARKET CAP

1.2B

P/E (TTM)

1.5x

FWD P/E

1.4x

DAY RANGE

$14 – $14

52W RANGE

$13
$16

The case for & against

Bull & Bear analysis

Bullish

Afya Limited (NASDAQ: AFYA) is a leading Brazilian company specializing in medical education and healthcare solutions. As a dominant player in the education sector, Afya focuses on undergraduate medical courses, continuous education, and medical practice solutions, encapsulated within an integrated ecosystem. By enhancing the skills of future medical professionals and improving healthcare delivery, Afya positions itself strategically in a growing market that thrives on the increasing demand for quality healthcare education.

Bull says

  • 4.7% dividend yield (41% payout) ranks in top 25% of peers
  • Q1 revenue BRL 1.013 bn (+8% YoY), net income BRL 257 m (+2% YoY)
  • Enrollment grew 2% to 26k students; CEO cites 20% organic intake rise
  • Free cash flow BRL 376 m and low leverage (BRL 1.62 bn debt) ensure flexibility
  • High earnings yield and positive price momentum attract income investors
  • Integrated medical education ecosystem supports expansion and potential M&A

Bear says

  • Negative analyst revisions reflect waning confidence in earnings trajectory
  • Elevated short interest signals market skepticism toward Afya’s outlook
  • Balance sheet flagged by negative QS score, raising stability concerns
  • Rising operational costs from new global tax may squeeze margins
  • Intense competition reduces candidates per seat, threatening enrollment growth
  • Low liquidity may deter institutional investors, adding share volatility

Earnings Call · Q4 2025 · Mgmt. Guidance

Updated 03-17-2026bullish

Transcript signals

Bull points

  • Our number of medical students grew 5% year over year, reaching more than 25,000 students, while approved medical seats increased by 5% in the fourth quarter of 2025.
  • adjusted EBITDA rose by 6%, reaching R$389 million, with an adjusted EBITDA margin of 42.6%. For the 12-month period, adjusted EBITDA amounted R$ 1,680 million, an increase of 15% over the prior year, with an adjusted EBITDA margin of 45.4%, representing a 130 base points increase over the same period.
  • Net income for the fourth quarter of 2025 came in at R$ 175 million, a marked increase of 14% over the same period in 2024, totaling R$768 million for the 12-month period, up 18% year-over-year.

Bear points

  • which are 220,000, down from the 238,000 in the same period of the prior year.
Read full transcript analysis ›